Dr. Jen Gunter

But when you look at the menopause society and, you know, the first statement that they released after the WHI, we actually read the papers.

They don't say women shouldn't be getting it for symptoms.

They say women shouldn't be getting it for primary cardio protection.

And the other issue that people have is that the study was stopped prematurely.

Well, so you and I know that with any clinical trial, you have a preset safety point.

that you stop the trial at.

Now the preset safety point doesn't mean that you've passed into some awful, terrible, dangerous range.

It means that, hey, maybe we shouldn't be continuing it because we might get there.

And if you're looking at a primary prevention trial, you can't be causing like more harm than good.

So they had this composite score

of stroke, death, breast cancer.

I think there were nine factors that went into this composite score, because they're kind of looking at net harm, net good.

And when that composite score hit the predetermined threshold, they stopped the study.

And that sounds like really reasonable when you talk about it this way.

That doesn't sound like the greatest harm ever done to women.

Imagine what would have happened if they hadn't stopped.

And then they had kept going.

And imagine if there had been a further increase in breast cancer that had crossed the predetermined safety threshold.

But they said, we don't care, we don't care.

And they kept going.